BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Advanced Research Projects Agency for Health (ARPA-H) has issued an Innovative Solutions Opening (ISO) for the BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) Program. This solicitation seeks groundbreaking solutions to address protein dysfunction in diseases like neurodegenerative conditions, cancers, and diabetes. ARPA-H anticipates awarding multiple Other Transaction (OT) Agreements. Solution Summaries are due March 4, 2026, and Full Proposals are due April 15, 2026.
Purpose & Scope
The BIOGAMI program aims to fundamentally transform therapeutic approaches by controlling protein folding and preventing aggregation. The scope includes:
- Technical Area 1 (TA1): Establish the "molecular grammar" of Intrinsically Disordered Regions (IDRs) through computational and experimental methods to characterize structural ensembles and biomolecular condensates.
- Technical Area 2 (TA2): Validate the foundational model from TA1 to develop detection and therapeutic applications. This involves creating methods to reverse protein aggregation, restore protein function, and validate clinical indicators for early detection, targeting both rare and non-rare diseases.
- Enabling Technologies: Proposers may leverage advanced biophysics, imaging, molecular dynamics simulations, AI/ML, and high-throughput assays. Open sharing of deidentified/sanitized data from TA1 activities is required.
Contract Details & Submission
- Contract Type: Multiple Other Transaction (OT) Agreements.
- Period of Performance: Two phases: Phase 1 (0-24 months) and Phase 2 (25-48 months).
- Set-Aside: None specified; all responsible sources are eligible, including universities, non-profits, small businesses, and other than small businesses. Proposers must have an active SAM.gov registration.
- Submission Process: A two-step process requiring a Solution Summary first, followed by an optional Full Proposal if encouraged.
- Key Deadlines:
- Solution Summaries: March 4, 2026
- Questions & Answers: March 11, 2026
- Full Proposals: April 15, 2026
Evaluation Criteria
Proposals will be evaluated based on:
- Overall Scientific and Technical Merit
- Proposer's Capabilities and/or Related Experience
- Potential Contribution to ARPA-H Mission and User Experience
- Assessment of Proposed Cost/Price
Important Information
A Proposers' Day was held on February 20, 2026 (details in separate Special Notice ARPA-H-SN-26-147). Commercialization plans (5-year and 10-year) are required prior to award. Proposers must review and complete various appendices, including the updated Cost Proposal Spreadsheet (Appendix F), Administrative National Policy (Appendix G), Security Attestation (Appendix H), Dangerous Gain of Function Assessment (Appendix I), and the Draft OT Agreement (Appendix J).